

## Special Issue

# Antibody Immunity against Emerging Pathogens

### Message from the Guest Editors

Emerging infections are a global health concern, and antibodies produced by the body fight invading pathogens. Antibodies have different mechanisms, can be antigen-specific, and are used to evaluate immune statuses. However, antibodies can also exacerbate disease severity and hinder vaccine development. This Special Issue aims to explore and understand the roles of antibodies in emerging and re-emerging viral infections, including profiling humoral responses, protective mechanisms, molecular mechanisms, improved strategies, therapeutic advances, and cross-reactive immunity. The objective is to delve into the following aspects in detail:

- Characterization of humoral responses during viral, bacterial or fungal infections.
- Identification of new protective mechanisms of antibodies during acute and chronic infections.
- Study of the molecular mechanisms of autoantibodies that worsen microbial infections.
- Advancements in strategies to elicit antibody responses through vaccination.
- Recent developments in therapeutic antibodies against microbial infections.
- Analysis of cross-reactive immunity following infection and vaccination.

---

### Guest Editors

Dr. Fok Moon Lum

A\*STAR Infectious Diseases Labs (ID Labs), Singapore, Singapore

Dr. Siew-Wai Fong

A\*STAR Infectious Diseases Labs (ID Labs), Singapore, Singapore

---

### Deadline for manuscript submissions

closed (31 January 2025)



## Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/195570](https://mdpi.com/si/195570)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).